Logo image of SABS

SAB BIOTHERAPEUTICS INC (SABS) Stock Price, Quote, News and Overview

NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock - Currency: USD

1.76  -0.02 (-1.12%)

SABS Quote, Performance and Key Statistics

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (5/28/2025, 4:10:58 PM)

1.76

-0.02 (-1.12%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.01
52 Week Low1
Market Cap16.35M
Shares9.29M
Float7.81M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/bmo
IPO01-12 2021-01-12


SABS short term performance overview.The bars show the price performance of SABS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

SABS long term performance overview.The bars show the price performance of SABS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SABS is 1.76 USD. In the past month the price decreased by -0.55%. In the past year, price decreased by -32.58%.

SAB BIOTHERAPEUTICS INC / SABS Daily stock chart

SABS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.83 323.41B
AMGN AMGEN INC 13.41 149.70B
GILD GILEAD SCIENCES INC 14.01 134.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.30B
REGN REGENERON PHARMACEUTICALS 13.36 63.90B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.23B
ARGX ARGENX SE - ADR 98.17 35.18B
ONC BEIGENE LTD-ADR 6.16 25.99B
BNTX BIONTECH SE-ADR N/A 23.45B
NTRA NATERA INC N/A 22.01B
SMMT SUMMIT THERAPEUTICS INC N/A 19.34B
BIIB BIOGEN INC 8.06 18.69B

About SABS

Company Profile

SABS logo image SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Miami Beach, Florida and currently employs 63 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Company Info

SAB BIOTHERAPEUTICS INC

777 W 41St St, Suite 401

Miami Beach FLORIDA US

CEO: Samuel J. Reich

Employees: 63

SABS Company Website

SABS Investor Relations

Phone: 13058452813

SAB BIOTHERAPEUTICS INC / SABS FAQ

What is the stock price of SAB BIOTHERAPEUTICS INC today?

The current stock price of SABS is 1.76 USD. The price decreased by -1.12% in the last trading session.


What is the ticker symbol for SAB BIOTHERAPEUTICS INC stock?

The exchange symbol of SAB BIOTHERAPEUTICS INC is SABS and it is listed on the Nasdaq exchange.


On which exchange is SABS stock listed?

SABS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SAB BIOTHERAPEUTICS INC stock?

10 analysts have analysed SABS and the average price target is 9.18 USD. This implies a price increase of 421.59% is expected in the next year compared to the current price of 1.76. Check the SAB BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SAB BIOTHERAPEUTICS INC worth?

SAB BIOTHERAPEUTICS INC (SABS) has a market capitalization of 16.35M USD. This makes SABS a Nano Cap stock.


How many employees does SAB BIOTHERAPEUTICS INC have?

SAB BIOTHERAPEUTICS INC (SABS) currently has 63 employees.


What are the support and resistance levels for SAB BIOTHERAPEUTICS INC (SABS) stock?

SAB BIOTHERAPEUTICS INC (SABS) has a support level at 1.78 and a resistance level at 1.86. Check the full technical report for a detailed analysis of SABS support and resistance levels.


Is SAB BIOTHERAPEUTICS INC (SABS) expected to grow?

The Revenue of SAB BIOTHERAPEUTICS INC (SABS) is expected to decline by -62.25% in the next year. Check the estimates tab for more information on the SABS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SAB BIOTHERAPEUTICS INC (SABS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SAB BIOTHERAPEUTICS INC (SABS) stock pay dividends?

SABS does not pay a dividend.


When does SAB BIOTHERAPEUTICS INC (SABS) report earnings?

SAB BIOTHERAPEUTICS INC (SABS) will report earnings on 2025-08-06, before the market open.


What is the Price/Earnings (PE) ratio of SAB BIOTHERAPEUTICS INC (SABS)?

SAB BIOTHERAPEUTICS INC (SABS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.7).


What is the Short Interest ratio of SAB BIOTHERAPEUTICS INC (SABS) stock?

The outstanding short interest for SAB BIOTHERAPEUTICS INC (SABS) is 1.28% of its float. Check the ownership tab for more information on the SABS short interest.


SABS Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to SABS. When comparing the yearly performance of all stocks, SABS is a bad performer in the overall market: 77.95% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SABS Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to SABS. SABS may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SABS Financial Highlights

Over the last trailing twelve months SABS reported a non-GAAP Earnings per Share(EPS) of -3.7. The EPS increased by 42.07% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -89.92%
ROE -160.11%
Debt/Equity 0.15
Chartmill High Growth Momentum
EPS Q2Q%6.67%
Sales Q2Q%-100%
EPS 1Y (TTM)42.07%
Revenue 1Y (TTM)-85.49%

SABS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to SABS. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 19.46% and a revenue growth -62.25% for SABS


Ownership
Inst Owners28.14%
Ins Owners18.43%
Short Float %1.28%
Short Ratio2.66
Analysts
Analysts84
Price Target9.18 (421.59%)
EPS Next Y19.46%
Revenue Next Year-62.25%